Search Beyond News…

PerZeption’s NEI SBIR grant funds early‑stage development of an optical diagnostic tool for age‑related macular degeneration

Executive summary: PerZeption Inc. was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute for a project titled “Efficient Achromatic and Chromatic Photostress Recovery Assessment for Age-related Macular Degeneration.” The grant provides non‑dilutive federal funding to develop a diagnostic tool that could improve early detection and monitoring of AMD, a leading cause of vision loss.

Who is involved: PerZeption Inc.; National Eye Institute (NEI); the SBIR program.

Likely next: PerZeption will use the funds to build and validate a prototype, with the possibility of applying for Phase II SBIR support or seeking clinical partnerships.

The National Eye Institute’s Phase I SBIR award gives PerZeption non‑dilutive financing to advance a photostress recovery assessment platform aimed at detecting and monitoring age‑related macular degeneration. Such grants are part of a broader federal effort to spur innovation in biomedical optics without diluting founder equity. While the award covers only initial feasibility work, a successful outcome could open the door to Phase II funding, clinical partnerships, or eventual regulatory clearance. At present, the announcement carries limited immediate market or regulatory impact.

What's next — scenarios

Base: Phase I prototype completed (50%)

PerZeption achieves technical milestones and prepares a Phase II SBIR application.

Upside: Strong clinical performance leads to Phase II award (30%)

Accelerated path toward FDA clearance and potential revenue from licensing or device sales.

Downside: Technical challenges limit follow‑on funding (20%)

Project stalls after Phase I, requiring alternative financing or a strategic pivot.

Timeline

Key entities

Sources

Browse the full archive →